Abaloparatide cost effective for postmenopausal osteoporosis

Abaloparatide cost effective for postmenopausal osteoporosis PharmacoEconomics & Outcomes News 804, p4 - 2 Jun 2018 Abaloparatide cost effective for postmenopausal osteoporosis Abaloparatide appears to be cost effective in patients with postmenopausal osteoporosis, according to findings of two studies reported in abstracts presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Cost effective in EU A Markov model was used to evaluate the cost effectiveness of 18 months’ treatment with abaloparatide compared with teriparatide (TPTD) or no treatment in patients with postmenopausal osteoporosis, from an EU perspective over a lifetime horizon. In a secondary analysis, abaloparatide was compared with denosumab (DMAB) and alendronic acid (ALN) in high-risk patients with vertebral fracture and bone mineral density (BMD) T-scores of –2.5 or lower, or with a 20% or greater 10-year risk of a major osteoporotic fracture. Abaloparatide was estimated to be dominant (less costly and more effective) compared with teriparatide. The estimated incremental cost-effectiveness ratio for abaloparatide compared with no treatment was below the WHO-recommended willingness-to-pay (WTP) threshold. In all age groups, abaloparatide was cost effective compared with denosumab and alendronic acid at a WTP threshold of €50 000 per QALY gained in patients with vertebral fracture and a low BMD T-score. "In patients at high risk of fragility fractures, abaloparatide is a cost-effective (dominant) alternative to teriparatide as well as antiresorptive agents DMAB and generic ALN," said the authors. . . . and in USA A Markov model was also used to evaluate the cost effectiveness of sequential treatment with either abaloparatide or teriparatide for 18 months, followed by alendronic acid for five years, for the prevention of osteoporotic fractures in patients with postmenopausal osteoporosis at increased risk of fracture, from a US payer perspective over a lifetime horizon. It was assumed patients were aged 50–80 years and had a BMD T-score of –3.5 or under, or between –2.5 and –3.5 and with a history of one or more osteoporotic fractures. Sequential abaloparatide and alendronic acid was dominant compared with sequential teriparatide and alendronic acid. In patients 70 years of age with a BMD T-score of –3.5 or under, sequential abaloparatide and alendronic acid was estimated to reduce the number of fractures by 0.125 per patient, increase the QALY gain by 0.036, and save $33 381 per patient compared with sequential teriparatide and alendronic acid. In probabilistic sensitivity analyses, abaloparatide and alendronic acid was dominant in 90% of the simulations. "Sequential ABL/ALN therapy is a cost-effective (dominant) strategy compared with sequential TPTD/ ALN therapy for the treatment of women at increased risk of fractures in the US," the authors concluded. 1. Hiligsmann M, et al. Cost-Effectiveness of Abaloparatide for the Treatment of Postmenopausal Women with Osteoporosis. 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases : abstr. OC3, 19 Apr 2. Hiligsmann M, et al. Cost-Effectiveness of Sequential Treatment with Abaloparatide vs. Teriparatide for the Prevention of Osteoporotic Fractures in Postmenopausal Us Women at Increased Risk of Fracture. 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases : abstr. P553, 19 Apr 2018. 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Abaloparatide cost effective for postmenopausal osteoporosis

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/abaloparatide-cost-effective-for-postmenopausal-osteoporosis-V0C23N1S8K
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-018-4968-1
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 804, p4 - 2 Jun 2018 Abaloparatide cost effective for postmenopausal osteoporosis Abaloparatide appears to be cost effective in patients with postmenopausal osteoporosis, according to findings of two studies reported in abstracts presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Cost effective in EU A Markov model was used to evaluate the cost effectiveness of 18 months’ treatment with abaloparatide compared with teriparatide (TPTD) or no treatment in patients with postmenopausal osteoporosis, from an EU perspective over a lifetime horizon. In a secondary analysis, abaloparatide was compared with denosumab (DMAB) and alendronic acid (ALN) in high-risk patients with vertebral fracture and bone mineral density (BMD) T-scores of –2.5 or lower, or with a 20% or greater 10-year risk of a major osteoporotic fracture. Abaloparatide was estimated to be dominant (less costly and more effective) compared with teriparatide. The estimated incremental cost-effectiveness ratio for abaloparatide compared with no treatment was below the WHO-recommended willingness-to-pay (WTP) threshold. In all age groups, abaloparatide was cost effective compared with denosumab and alendronic acid at a WTP threshold of €50 000 per QALY gained in patients with vertebral fracture and a low BMD T-score. "In patients at high risk of fragility fractures, abaloparatide is a cost-effective (dominant) alternative to teriparatide as well as antiresorptive agents DMAB and generic ALN," said the authors. . . . and in USA A Markov model was also used to evaluate the cost effectiveness of sequential treatment with either abaloparatide or teriparatide for 18 months, followed by alendronic acid for five years, for the prevention of osteoporotic fractures in patients with postmenopausal osteoporosis at increased risk of fracture, from a US payer perspective over a lifetime horizon. It was assumed patients were aged 50–80 years and had a BMD T-score of –3.5 or under, or between –2.5 and –3.5 and with a history of one or more osteoporotic fractures. Sequential abaloparatide and alendronic acid was dominant compared with sequential teriparatide and alendronic acid. In patients 70 years of age with a BMD T-score of –3.5 or under, sequential abaloparatide and alendronic acid was estimated to reduce the number of fractures by 0.125 per patient, increase the QALY gain by 0.036, and save $33 381 per patient compared with sequential teriparatide and alendronic acid. In probabilistic sensitivity analyses, abaloparatide and alendronic acid was dominant in 90% of the simulations. "Sequential ABL/ALN therapy is a cost-effective (dominant) strategy compared with sequential TPTD/ ALN therapy for the treatment of women at increased risk of fractures in the US," the authors concluded. 1. Hiligsmann M, et al. Cost-Effectiveness of Abaloparatide for the Treatment of Postmenopausal Women with Osteoporosis. 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases : abstr. OC3, 19 Apr 2. Hiligsmann M, et al. Cost-Effectiveness of Sequential Treatment with Abaloparatide vs. Teriparatide for the Prevention of Osteoporotic Fractures in Postmenopausal Us Women at Increased Risk of Fracture. 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases : abstr. P553, 19 Apr 2018. 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off